Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.72), $0.38 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.39 million versus the consensus estimate of $25.8 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.